Transrectal ultrasound-guided (TRUS) prostate biopsy is an established procedure for diagnosis of prostate cancer. Complications after TRUS biopsy are not well reported in Hong Kong. This study evaluated the 5-year incidences of TRUS biopsy complications and potential risk factors for those complications.
Introduction
Transrectal ultrasound-guided (TRUS) prostate biopsy, introduced in 1989, 1 is an established and longstanding procedure for detection of prostate However, TRUS biopsy is associated with significant risks. Instances of bleeding are common, including haematuria, rectal bleeding, and haemospermia; however, these are generally mild and self-limiting. 4 The most worrisome complication is post-biopsy infection, which occurs in 0% to 6.3% of men after TRUS biopsy. 4 The risk is low, but the consequences are serious in affected patients. There is recent evidence to suggest that increasing numbers of quinolone-resistant organisms are contributing to the development of post-biopsy sepsis. 4 In Hong Kong, there have been few reports of TRUS biopsy complications. Some studies have focused on infective complications in relatively small numbers of patients. 5, 6 Therefore, we reviewed TRUS biopsies performed over a 5-year period in two local hospitals to evaluate the incidences and types of complications, as well as their associated risk factors. This could provide an important insight into the overall TRUS biopsy complications, including infective and non-infective complications in the local population.
Methods

Patients and study design
This retrospective cohort analysis included men who underwent TRUS biopsy procedures during the period from 2013 to 2017 in United Christian Hospital, Hong Kong and Tseung Kwan O Hospital, Hong Kong. All patients who underwent TRUS biopsy procedures were included in the analysis.
Indications for biopsy included elevated prostatespecific antigen (PSA) level, suspicious digital rectal examination of the prostate, restaging biopsies in incidental prostate cancer detected in transurethral prostatectomy or in patients under active surveillance of prostate cancer, and previous suspicion of prostate cancer (eg, high-grade prostate intraepithelial neoplasia or atypical small acinar proliferation). Pre-biopsy blood tests were performed to determine complete blood count, clotting profile, and PSA level. Mid-stream urine was collected 3 to 4 weeks prior to biopsy for bacterial culture analysis. A course of antibiotic treatment was administered if pre-biopsy bacteriuria was detected, based on the sensitivity profile of the involved bacteria. Anticoagulant medications and clopidogrel were discontinued prior to biopsy; the duration of cessation and any requirement for heparin coverage were determined by physicians. The use of low-dose aspirin was continued during biopsy. Oral bisacodyl tablets were used for rectal preparation on the morning of the biopsy procedure. Quinolone antibiotic prophylaxis with oral levofloxacin 500 mg was prescribed 1 hour prior to biopsy, then continued for 2 days after biopsy. This report was compiled in accordance with the STROBE guidelines. 7 The principles outlined in the Declaration of Helsinki were followed.
Biopsy procedure
All biopsies were performed as day procedures. A 7.5-MHz biplanar transrectal ultrasound probe and 18-gauge needles with side-firing needle-guides were used for biopsy. Each patient was positioned in the left lateral posture with both hips and knees flexed. Prostate size measurement was calculated using the ellipsoidal formula. Topical lidocaine jelly and local anaesthetic injection with 10 mL of 1% plain lidocaine were used routinely in one hospital; these were injected into the area between the prostatic base and seminal vesicles. The other hospital used topical lidocaine alone. Six-core to 12-core systemic biopsies were performed depending on the hospital involved and the time frame of the biopsy procedure, as the two centres have changed the practice in performing more number of cores with time. Each patient was discharged on the same day after completion of the procedure. Clinical follow-up was performed at 4 weeks post-biopsy in an out-patient clinic to review the pathology findings.
Follow-up assessment
Patients who were admitted for biopsies were identified using the Clinical Data Analysis and Reporting System. Clinical records (ie, discharge summary, emergency case notes, clinic consultation notes, laboratory results, and ultrasound findings) were retrieved using the hospital-based Clinical Management System and the territory-wide Electronic Patient Record, which comprises a centralised medical records system shared by all public hospitals. Thus, men who had been admitted to another public hospital for complications could be identified. The patients' records were examined and the occurrence of complications was determined using a standardised form. During post-biopsy follow-up examinations, clinical records from the Clinical Management System were examined to identify any potential attendances or admissions to private sector hospitals owing to complications. The primary outcome in this study was the occurrence of complications within 30 days after biopsy. Complications were defined as events requiring either emergency attendances or hospitalisations; these events were analysed separately. Post-biopsy urinary tract infections (PBI) were defined as the presence of urinary tract infection symptoms (dysuria, with or without frequency, urgency, or suprapubic pain) after biopsy, with or without sepsis. Based on the Sepsis-3 criteria, sepsis was defined as an acute increase in the Sequential Organ Failure Assessment score of ≥2. 8 Acute urinary retention (AUR) was defined as acute painful retention of urine requiring catheterisation. Any lower urinary tract symptoms (LUTS) that occurred or worsened after biopsy, which required emergency attendances, were also recorded.
Statistical analysis
Statistical calculations were computed with the SPSS (Windows version 22.0; IBM Corp, Armonk [NY], United States). For examination of potential risk factors, continuous variables, such as PSA level and prostate size, were categorised based on the median values. The Chi squared test was used to compare complications between the two hospitals. Multiple logistic regression models were used to investigate potential risk factors for complications.
Results
In total, 1710 men were admitted to either of the two hospitals for TRUS biopsy procedures during the study period. Eleven men were excluded because they refused to undergo TRUS biopsy after admission; therefore, 1699 men were included in the study. The mean age (± standard deviation) of the men was 67 ± 7 years and median PSA level was 7.9 µg/L (interquartile range, 5.5-12.6 µg/L). Of the 1699 men in the study, 310 (18.2%) had a suspicious digital rectal examination of the prostate; the overall cancer detection rate was 19.8%. Characteristics and results of the biopsies are shown in Table 1 . Overall, 5.7% and 3.8% of post-biopsy complications required emergency attendances and hospitalisations, respectively ( Table 2 ). There were no occurrences of mortality in the entire cohort. (Table 3) . Importantly, the continuation of low-dose aspirin was not associated with an increased rate of bleeding complications.
Retention of urine and lower urinary tract symptoms
In all, 1.5% of men in the study developed AUR; all required hospitalisations. During these hospitalisations, the men were assessed by voiding trials; all were able to void spontaneously within 2 to 3 days. Acute-onset LUTS was present in 0.4% of men who had emergency attendances, and 0.1% of the men required hospitalisation. Prostate size >48 cc was associated with a nearly 3-fold increase in the risk of post-biopsy retention (odds ratio=2.75, 95% confidence interval: 1.23-4.17; Table 3 ). No risk factors were identified with respect to the occurrence of LUTS.
Post-biopsy infection
Pre-biopsy bacteriuria was present in 4.3% of men in this study. The most common causative bacterial species was Escherichia coli (1.8%) [ Table 4 ]. Emergency attendances and hospitalisation rates for PBI were 1.9% and 1.2%, respectively. Sepsis occurred in 0.9% of men in this study, all of whom required hospitalisations ( Abbreviations: AUR = acute urinary retention; CI = confidence interval; OR = odds ratio; PSA = prostate-specific antigen Treatment for bacteriuria and the presence of diabetes mellitus both showed no associations with overall infection or urosepsis. No other factors tested including age and prostate size were associated with infective complications. There were no differences in the rates of overall complications requiring either emergency attendances (6.5% vs 4.6%, P=0.10) or hospitalisations (3.9% vs 3.8%, P=0.95) between the two hospitals. Moreover, there were no differences in the rates of overall post-biopsy infection or sepsis (0.8% vs 1.6%, P=0.13 and 0.5% vs 1.4%, P=0.19).
Discussion
Non-infective complications
Non-infective complications after TRUS biopsy were common in this study; fortunately, most comprised minor complications that did not require additional treatment. Using questionnaires and telephone for follow-up of patients who underwent TRUS biopsy, the ProtecT Study group found that haematuria occurred in 65.8%, rectal bleeding occurred in 36.8%, and haemospermia occurred in 92.6%, within 35 days after biopsy. 9 A recent systematic review of TRUS biopsy complications reported wider ranges of complication rates: haematuria in 27.9% to 64.5% of patients, haemospermia in 6% to 90.1% of patients, and rectal bleeding in 11.5% to 40% of patients. 4 These wide ranges of complication rates were largely dependent on the methods by which the complications were registered. In our study, the reported bleeding rate was lower, as we only included patients with complications requiring emergency attendances. The differences in our findings suggest that post-biopsy bleeding might generally be mild; thus, it does not require medical consultation.
Prostate size is reportedly associated with the risk of haematuria after biopsies, as is the number of cores, although this particular point remains controversial. [10] [11] [12] However, our study did not find evidence to support these relationships. The postbiopsy retention rate in our study was comparable with that in the literature (0.2%-1.7%). 4 All men had successful voiding trials in our cohort and did not require surgical intervention. Importantly, we found that prostate size was a risk factor for post-biopsy retention, consistent with the results of two other studies. 10, 11 
Infective complications
Infective complications requiring hospitalisation have been reported in 0% to 6.3% of patients after TRUS biopsy. 4 The Global Prevalence Study of Infections in Urology 2013 revealed post-biopsy infection in 5.2% of patients; of them, 3% required hospitalisation. 3 A recently published populationbased study showed an increasing trend in infective complications, comprising a four-fold increase in overall hospitalisations over 10 years. 13 In the present study, we could not perform any temporal analyses of complications because the length of the study was insufficient; to the best of our knowledge, there have been no such temporal analyses in Hong Kong. The infection rate in our cohort was comparatively lower than that of most international studies, 4 and similar to that in prior studies elsewhere in Asia 14, 15 (0% and 0.5% of PBI), as well as in Hong Kong 5,6 (0.5% and 3.9%). Reasons for the apparent lower infection rate in people of Asian ethnicity compared with those of other ethnicities are unclear. Tsu et al 6 reported that patients who underwent TRUS biopsy exhibited a high prevalence (53.6%) of antibiotic-resistant flora in the rectum, although the PBI rate remained low among these patients (2.4%). Numerous risk factors have been associated with the development of PBI. 4 However, in the present study, we did not identify any factors that could predict the risk of PBI.
A positive urine culture was not a mandatory requirement to define PBI in this study, as a significant proportion of men who had urinary tract infection symptoms without systemic inflammatory response syndrome were treated and discharged directly from the emergency department, and most did not provide urine cultures. Thus, the emergency case notes were reviewed to determine whether PBI had occurred. In contrast, for men who had been hospitalised with sepsis, urine and blood cultures were available for analysis.
There were no reports of mortality in our cohort. In general, death directly related to biopsy is exceedingly rare and most patients die because of other factors. The reported mortality rates after TRUS biopsy are 0.09% to 1.3%, depending on the length of the post-biopsy follow-up period. 4 Data from a prostate cancer screening trial showed a mortality rate of 0.095% in biopsy patients, which was comparable to that of the control group. Notably, the mortality rate in biopsy patients was lower than that in patients who had no biopsies; none of the deaths in the study were related to the biopsy procedure. 16
Transperineal or transrectal approaches
There has been a recent surge of interest, both in Hong Kong and internationally, in performing transperineal prostate biopsies. Transperineal biopsies are advantageous in that they have an extremely low risk of sepsis and enable improved sampling of tumours in the anterior prostate. 17 In transperineal biopsy, the needle is passed through clean and prepared skin, rather than faeces or bowel; this method is presumed to eliminate post-biopsy infection. In 2013, a large systematic review of transperineal biopsy showed no instances of sepsis, with only a few reported cases of PBI (0%-1.6%). 4 Transrectal biopsy exhibits difficulty in sampling the anterior prostate. Indeed, transperineal biopsy reportedly exhibits a superior cancer detection rate, especially in terms of tumours in the anterior prostate. 18, 19 Despite these advantages in the rate of postbiopsy sepsis and sampling of anterior tumours, the transperineal approach has limitations. These include longer operating time, greater procedurerelated pain, and increased post-biopsy retention, particularly in relation to the use of template mapping protocols. 20, 21 A systematic review and meta-analysis conducted in 2012, which compared the outcomes of transperineal and transrectal biopsies, did not show any differences in rates of complications between the two approaches. 22 In our opinion, additional studies are needed to compare the two approaches in terms of cancer detection rate, complications, cost-effectiveness, and patient-reported outcomes before wide adoption of the transperineal approach is recommended.
In early 2018, we began exploratory use of transperineal prostate biopsy; thus far, we have used it for assessment of 71 patients. None of the patients have shown signs of sepsis or urinary tract infections; two patients were readmitted after biopsy for urethral bleeding and three patients were readmitted for urinary retention. The number of biopsies performed thus far is insufficient for a meaningful comparison with existing data from transrectal biopsies.
Limitations and future studies
To the best of our knowledge, this is the first study in Hong Kong to provide data regarding non-infective complications of TRUS biopsy. It provides valuable information for patients and can be used by clinicians during treatment counselling. Special precautions and education are needed for patients with a large prostate, as they exhibit an increased risk of postbiopsy retention. Nonetheless, the value of this study was limited by its retrospective nature.
The complications recorded were based solely on emergency attendances and hospitalisations in all public hospitals; importantly, attendances to private sector hospitals might have been missed. However, because approximately 90% of in-patient care in Hong Kong is provided by public hospitals, we presume that our approach enabled us to retrieve data regarding the vast majority of post-biopsy complications that required hospitalisations. 23 In addition, patients who had attended private hospitals for complications, then attended public out-patient clinics for follow-up, could be identified and recorded unless they also selected private clinic follow-up.
Milder complications which did not require emergency attendances or hospitalisations, as well as sexual dysfunction and post-biopsy pain, could not be assessed in this study. Because of its retrospective design, we also could not report on prior antibiotics exposure and travel history among the patients, which limits analyses of risk factors. The number of cores taken could have affected the rate of complications. 4 Approximately 20% of men in the cohort had sextant biopsies. The use of this lower number of cores might have led to underestimation of the rate of complications, compared with current standards for biopsy, in which 10 to 12 cores are taken.
Finally, a locoregional prospective multicentre study with other Asian nations would provide valuable insights into complications after prostate biopsies in the Asian population; it would also aid in assessments of differences in complications compared with Western nations.
Conclusions
Complications requiring emergency attendances or hospitalisations after transrectal prostate biopsy were uncommon; the most common complications requiring emergency attendances and hospitalisations were gross haematuria and AUR, respectively. Prostate volume >48 cc was a risk factor for post-biopsy urinary retention, but no specific risk factors were identified for post-biopsy infections. Patients with large prostate should be counselled for the increased risk of urinary retention after TRUS biopsy.
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